Premature Ejaculation Study: Research, Clinical Trials and Evidence for Maca or Garlic

Premature ejaculation (PE) has been studied in hundreds of research papers and dozens of randomised clinical trials. The quality of evidence differs substantially between treatments, and the strongest support still sits with established pharmacological options such as selective serotonin reuptake inhibitors, dapoxetine and topical local anaesthetics.

For adults in the UK looking for evidence-based information on PE research — whether you are considering treatment, reviewing trial data or checking claims about supplements — the key issue is not simply whether a premature ejaculation study exists, but what kind of study it is, how PE was measured, and whether the results are clinically relevant. This is where measures such as intravaginal ejaculatory latency time (IELT), trial design and patient selection become important.

More recent research is examining pelvic-floor rehabilitation, magnetic stimulation, combination treatment and experimental medicines, while popular natural products such as maca root and garlic have far weaker PE-specific evidence.

This difference matters because a search for a “premature ejaculation study” can bring up very different levels of evidence. A randomised placebo-controlled trial involving men diagnosed with PE carries far more weight than a laboratory experiment, animal study, case report, traditional-use reference or study looking at a different outcome such as sperm concentration. A treatment may also appear on a clinical-trial registry before researchers have published any results: registration shows that researchers plan to study the intervention, not that effectiveness has been shown. This article helps you interpret those differences, compare established treatments with newer therapies and natural supplements, and avoid giving equal weight to evidence that is not equally reliable.

Key things to know

Premature ejaculation research increasingly examines more than ejaculation time alone, and modern sexual medicine's guidelines view assessment and treatment through a biopsychosocial framework. Modern trials may assess:

ejaculation latency

perceived control

PE-related distress

patient-reported improvement

treatment satisfaction

adverse effects

quality of life.

Broad premature ejaculation prevalence reporting suggests about 30% of men aged 18 to 59 report it, although that does not reflect a single strict diagnostic standard.

A 2025 umbrella review examined 44 systematic reviews and meta-analyses covering 65 randomised controlled trials of pharmacological PE treatment. The authors found meaningful improvements with several treatments but also noted major differences in trial quality and considerable heterogeneity. Only 6 of the 65 underlying trials were judged to have a low risk of bias.

That finding explains why one positive PE study should never be interpreted as definitive proof.

What Does Lifelong Premature Ejaculation Research Study?

PE research generally asks several different questions.

Researchers may investigate:

Does treatment increase ejaculation latency?

This is commonly measured using intravaginal ejaculatory latency time, usually shortened to IELT.

Does the person feel more control?

A treatment that adds time but does not improve perceived control may have limited practical value.

Does treatment reduce distress?

Modern PE research recognises that the condition is not defined by timing alone, which is why researchers also assess distress alongside psychological factors such as anxiety and stress.

Untreated premature ejaculation symptoms can be associated with broader negative personal consequences, including clinical depression in some individuals.

Does treatment remain effective?

Short studies may show an early benefit without establishing whether the effect lasts.

What adverse effects occur?

Treatment should provide a meaningful net benefit rather than simply creating the longest possible ejaculation delay.

What Is IELT in Premature Ejaculation Studies?

IELT means intravaginal ejaculatory latency time.

It measures the interval between penetration and ejaculation and is one of the most commonly used objective outcomes in PE research.

Trials may measure IELT using:

a stopwatch

participant estimation

diary records.

Stopwatch measurement is generally more objective, although it can make participants more aware of timing.

IELT should not be treated as the only measure of success. In diagnostic context, lifelong premature ejaculation is commonly associated with an intravaginal ejaculation latency time of under 1 minute, while acquired premature ejaculation is often under 3 minutes.

Modern diagnostic approaches also consider:

ability to delay ejaculation

distress

consistency

whether the pattern is lifelong or acquired.

A 2026 urological review emphasised that ejaculation latency is useful for measuring severity but is insufficient as a standalone diagnostic criterion.

What Is a Premature Ejaculation Clinical Trial?

A clinical trial is a structured research study involving human participants.

For PE, researchers might compare:

active treatment vs placebo

one medicine vs another

medicine vs behavioural treatment

or

combined treatment vs one treatment alone.

The strongest studies generally use randomisation.

Randomisation reduces the chance that people receiving one treatment differ systematically from those receiving another.

Blinding can provide further protection against bias by preventing participants or researchers from knowing which treatment was assigned.

Start Your Free Assessment

What Is a Randomised Controlled Trial?

A randomised controlled trial, or RCT, assigns participants to different treatment groups using a random process.

For example:

Group A: active PE treatment

Group B: placebo.

Researchers then compare outcomes after treatment.

RCTs are particularly useful because PE outcomes can be influenced by:

expectation

anxiety

relationship circumstances

natural variation

behavioural changes during the study.

A treatment that appears beneficial in an uncontrolled study may perform differently when compared with placebo.

Does One Positive PE Study Prove a Treatment Works?

No.

One study can produce an encouraging result while still having major limitations.

Important questions include:

How many participants were included?

Was treatment randomised?

Was there a placebo group?

Were participants blinded?

How was PE diagnosed?

Was ejaculation time objectively measured?

How long did follow-up last?

How many participants stopped treatment?

Were adverse effects reported?

Has another independent research group reproduced the result?

Systematic reviews and meta-analyses help answer these questions by combining evidence from multiple trials.

What Does the Latest Broad Research Say About PE Medicines?

A major 2025 umbrella review evaluated meta-analyses of randomised PE treatment trials.

It ultimately incorporated evidence from 65 RCTs.

The analysis found significant ejaculation-latency improvements with treatments including:

SSRIs

topical local anaesthetics

tramadol.

Paroxetine produced one of the largest average improvements in the pooled analysis and is often regarded as the most effective SSRI in comparative PE research.

However, evidence quality was not uniformly strong. Only topical local anaesthetics and paroxetine achieved moderate-to-high evidence ratings in that analysis, and the researchers highlighted substantial heterogeneity between studies.

This does not mean those are automatically the right treatment for everyone.

UK treatment selection also considers licensing, safety, on-demand versus continuous dosing and individual medical history. Even when short-term trial results are positive, medical therapy can still be limited by poor long-term drug adherence.

What Does Research Say About Selective Serotonin Reuptake Inhibitors (SSRIs)?

SSRIs are among the most extensively investigated medicines for premature ejaculation.

They modify serotonin signalling involved in neurological ejaculation control and are also discussed within the broader management of sexual dysfunction.

Studies have examined:

dapoxetine

paroxetine

sertraline

fluoxetine

other serotonergic medicines.

Clinical research generally shows that these medicines can increase ejaculation latency and improve perceived control.

However, conventional antidepressant SSRIs used specifically for PE are often off-label, whereas dapoxetine was developed specifically as an on-demand PE treatment. SSRIs used in this setting can also cause sexual side effects, including decreased libido and anorgasmia.

Current British specialist guidance therefore distinguishes licensed PE treatment from routine use of longer-term off-label antidepressants.

What Does Research Say About Topical Treatments?

Topical local anaesthetics have one of the stronger evidence bases for premature ejaculation. They reduce sensory transmission from the glans and may make ejaculation more difficult to trigger.

Clinical research has investigated lidocaine-containing products and lidocaine/prilocaine preparations. The UK Health Research Authority has also published information on research involving PSD502, a metered-dose anaesthetic spray developed for premature ejaculation. Its research summary notes that previous clinical studies included 556 men with PE and reported increased ejaculation time, although the HRA page itself describes a separate safety and tolerability study in healthy female volunteers.

These findings provide research context for topical anaesthetic treatments, but individual trials should still be assessed according to their design, participants, outcomes and published results.

What Are Current Premature Ejaculation Clinical Trials Studying?

Research continues to move beyond established medicines.

As of 2026, registered trials include investigations of:

• pelvic-floor muscle training
• biofeedback
• electromagnetic pelvic-floor stimulation
• experimental medicines
• combination therapies.

For example, a 2026 recruiting randomised trial plans to compare three pelvic-floor approaches in 150 men with lifelong PE: electromagnetic stimulation, biofeedback-assisted training and conventional pelvic-floor muscle training.

Another trial updated in January 2026 is recruiting participants to study pelvic-floor therapy for erectile difficulties and PE.

These trials show where research is going, but they should not be cited as proof of effectiveness before results are available.

Are Pelvic-Floor Treatments Supported by Research?

Evidence is increasingly promising.

A 2026 systematic review and meta-analysis evaluated randomised trials of pelvic-floor muscle training for PE.

The review concluded that pelvic-floor training may improve ejaculation latency, while highlighting the continuing need for larger, more standardised trials.

Pelvic-floor treatment is particularly interesting because it provides a non-drug approach. In this context, pelvic floor exercises, including Kegel exercises, aim to strengthen pelvic floor muscles and may improve ejaculatory control in men with PE.

However, the term “pelvic-floor treatment” can include several different techniques:

• muscle training
• relaxation
• biofeedback
• physiotherapy
• behavioural techniques

Examples include the stop-start and squeeze methods, and the squeeze technique has been reported to help some patients regain control over ejaculation. Some studies also discuss masturbating before sexual intercourse as a way to delay ejaculation.

Evidence for one technique should not automatically be applied to all of them.

Is Electromagnetic Treatment Being Studied?

Yes.

A trial registered in 2026 is directly comparing electromagnetic pelvic-floor stimulation with conventional pelvic-floor training and biofeedback-assisted training in men with lifelong PE.

Another completed 2026 study compared pelvic-floor muscle training alone with pelvic-floor training plus extracorporeal magnetic innervation. The registry currently describes the study design, but registration alone should not be interpreted as evidence of clinical benefit.

This distinction is important because commercial promotion can sometimes move faster than published research. Psychological therapy, including cognitive behavioral therapy, may also improve ejaculatory control and satisfaction and is often considered alongside physical approaches.

Start Your Free Assessment

Are New PE Medicines Still Being Studied?

Yes.

A Phase 2a trial registered in 2026 is evaluating an experimental treatment called KH-001 in approximately 40 men with lifelong PE.

The study uses a double-blind, placebo-controlled crossover design and is examining ejaculation latency, patient-reported outcomes and safety.

Because the trial is still research rather than established practice, it should not be presented as an available proven treatment.

What Does “Recruiting” Mean on a Clinical-Trial Registry?

Recruiting means researchers are currently seeking eligible participants.

It does not mean:

• the medicine works
• regulators have approved the treatment
• results have been published
• safety has been established.

Similarly, “completed” means the planned trial activity has ended.

It does not automatically mean the study produced positive findings.

The results must still be analysed and ideally published in a peer-reviewed journal.

What Is a Premature Ejaculation Case Study?

The term case study usually refers to detailed information about one person or a very small group.

A case study may be useful when:

• a treatment is new
• an unusual condition is involved
• researchers notice an unexpected response.

However, case studies provide relatively weak evidence of effectiveness.

If one man improves after trying a treatment, researchers cannot easily determine whether improvement resulted from:

• the treatment
• placebo effects
• reduced anxiety
• relationship changes
• another simultaneous treatment
• natural variation.

A case study can generate a research hypothesis.

It cannot reliably establish how well a treatment works across a population.

Case Study vs Clinical Trial: Which Is Better Evidence?

Generally:

Evidence type	What it can tell us	Relative strength
Case report	What happened to one person	Low
Case series	Outcomes in several people	Low
Observational study	Associations in larger groups	Moderate for associations
Controlled trial	Comparison between treatments	Stronger
Randomised controlled trial	Better test of causality	Strong
Systematic review/meta-analysis	Overall findings across studies	Potentially strongest

Evidence quality still depends on how well each study was performed.

A poor systematic review of weak studies does not automatically become excellent evidence.

What Is a Systematic Review?

A systematic review uses a predefined method to identify and assess all relevant research answering a particular question.

Researchers typically:

1. define the research question
2. search multiple databases
3. apply inclusion criteria
4. evaluate study quality
5. extract results
6. compare or combine findings.

Systematic reviews are especially valuable when individual PE trials produce conflicting results.

What Is a Meta-Analysis?

A meta-analysis statistically combines results from multiple studies.

This can produce a more precise estimate than one small trial.

However, pooling only makes sense when the studies are sufficiently comparable.

PE meta-analyses often face challenges because studies vary in:

• PE definitions
• treatment doses
• treatment duration
• participant age
• lifelong versus acquired PE
• outcome measurement.

The 2025 umbrella review specifically highlighted substantial heterogeneity across the pharmacological PE literature.

What Is the Evidence for Natural PE Treatments?

Natural and complementary treatments have been studied, but the overall evidence base is considerably weaker and more heterogeneous than for established PE medicines.

A systematic review of complementary interventions found only 10 randomised trials, covering treatments such as acupuncture, Chinese herbal preparations, Ayurvedic medicine and a topical herbal product.

The researchers found preliminary positive signals but concluded that the studies were clinically heterogeneous, often had unclear risk of bias and reported adverse effects inconsistently.

A broader 2023 systematic review identified 22 controlled trials of traditional or complementary approaches to ejaculation disorders, 21 of which involved PE. Only about 32% of the included studies were judged to have a low risk of bias, and the interventions varied substantially.

Is There a Maca Premature Ejaculation Study?

There is no strong human PE-specific clinical-trial evidence establishing maca root as an effective treatment for premature ejaculation.

This is important because maca has been researched in men—but most human maca studies have examined different outcomes.

These include:

• desire
• erectile function
• semen parameters
• sperm concentration
• sperm motility
• hormone measurements.

A systematic review of maca clinical research found only four relevant randomised trials assessing broader intimate function, and concluded that the evidence was too limited to draw firm conclusions about effectiveness.

That research should not be misrepresented as proof that maca treats PE.

What Did Maca Studies Actually Measure?

One frequently cited randomised trial involved healthy men who received maca for 12 weeks.

The main outcome was self-reported desire, alongside mood and hormone measurements.

The study was not designed as a premature ejaculation treatment trial.

Other maca studies have focused primarily on semen.

A small randomised pilot trial involving 20 healthy men studied maca for 12 weeks and evaluated:

• semen parameters
• reproductive hormones
• thyroid-related measurements.

Again, premature ejaculation was not the principal treatment question.

Does Maca Improve Ejaculation Time?

There is currently insufficient human clinical evidence to say that maca reliably increases ejaculation latency in men with PE.

Some animal studies have measured ejaculation behaviour, but animal findings cannot be directly converted into human PE treatment recommendations.

In fact, older animal research involving maca extracts sometimes found shorter ejaculation latency, which would not support presenting maca as an established ejaculation-delaying treatment.

Human evidence needs to be prioritised.

Start Your Free Assessment

Does Maca Improve Testosterone?

Maca should not be described as a proven testosterone-boosting PE treatment.

A randomised study of healthy men found increased self-reported desire after maca but no corresponding change in serum testosterone.

Other human maca studies examining semen parameters have similarly failed to establish a simple testosterone-mediated effect.

This matters because marketing sometimes incorrectly links:

maca → higher testosterone → longer ejaculation time.

The evidence does not establish that pathway.

Does Maca Improve Sperm Quality?

Maca has been researched more extensively for semen parameters than for premature ejaculation.

However, even this evidence is inconsistent.

A 2022 systematic review and meta-analysis identified five randomised trials and found mixed results for sperm concentration and motility. The pooled analysis did not demonstrate a significant improvement in sperm concentration compared with placebo.

Semen quality is also a completely different outcome from ejaculation control.

Evidence that a supplement affects sperm does not prove it delays ejaculation.

Can Maca Root Be Recommended for Premature Ejaculation?

Not as an evidence-based PE treatment on current human research.

Someone may choose to use maca as a food supplement for other reasons, but it should not be promoted as clinically proven to:

• cure PE
• increase ejaculation time
• correct serotonin signalling
• permanently improve control.

Established PE treatments have much more direct evidence.

What Is the Evidence for Garlic and Premature Ejaculation?

Evidence is even weaker.

Garlic, or Allium sativum, appears in some traditional medicinal databases as a plant historically associated with PE management.

However, a traditional-use listing is not the same as a randomised human clinical trial.

For example, one medicinal-plant database lists garlic for PE based on traditional-reference material rather than providing modern PE-specific efficacy trials.

Current systematic reviews of complementary PE treatments do not establish ordinary garlic supplementation as a proven treatment.

Is There Good Garlic Premature Ejaculation Evidence?

At present, there is not good-quality human clinical evidence showing that eating garlic or taking a garlic supplement reliably delays ejaculation in men diagnosed with PE.

That means claims such as:

“garlic cures PE”

“garlic permanently increases ejaculation time”

or

“garlic works like PE medicine”

are not supported by current clinical evidence.

Traditional use can provide ideas for research, but it cannot replace controlled human trials.

Could Garlic Help Indirectly Through Cardiovascular Health?

Garlic has been researched in other areas of health, but evidence for those outcomes cannot simply be transferred to premature ejaculation.

Even if an intervention benefits one aspect of cardiovascular health, that does not establish a direct effect on neurological ejaculation control.

PE has multiple possible mechanisms involving:

• serotonin signalling
• neurological control
• psychological factors
• erection problems
• prostate or pelvic conditions
• sensory pathways.

A general health effect is therefore not equivalent to PE efficacy.

Should Garlic Be Taken as a PE Supplement?

There is not enough evidence to recommend garlic supplements specifically for treating premature ejaculation.

Garlic consumed normally as food is different from concentrated supplements.

Supplements can also:

• cause digestive effects
• interact with medicines
• increase bleeding tendency in some circumstances.

Someone taking regular medication should discuss concentrated herbal products with a pharmacist or clinician.

Why Do Maca and Garlic Appear in PE Searches?

Several factors contribute.

Natural remedies often gain search popularity because they are:

• inexpensive
• widely available
• perceived as safer
• promoted through forums
• associated with traditional medicine
• marketed using broader male-health claims.

Search popularity does not measure clinical effectiveness.

A substance can receive thousands of online searches while having very little PE-specific human research.

Does “Natural” Mean Clinically Proven?

No.

Natural products still need appropriate clinical research.

For PE, a useful supplement trial would ideally:

• recruit men meeting recognised PE criteria
• use random allocation
• include placebo
• use standardised supplement composition
• measure ejaculation latency
• measure control and distress
• report adverse effects
• provide adequate follow-up.

Without these features, it is difficult to distinguish treatment effect from expectation or natural variation.

Why Is Standardising Herbal Research Difficult?

Two supplements labelled with the same plant name can contain different amounts of active compounds.

Variation can result from:

• plant variety
• growing conditions
• harvesting
• processing
• extraction method
• storage
• supplement formulation.

This creates problems when trying to reproduce clinical results.

A standard prescription medicine has a defined active ingredient and dose, whereas herbal preparations may be much more variable.

Can Supplements Interact With PE Medicines?

Yes.

Natural products should not automatically be assumed safe alongside prescription treatment.

Potential interactions can involve:

• blood pressure
• bleeding
• liver metabolism
• serotonin pathways
• other medicines.

Always disclose supplements during a PE consultation, particularly if you are considering:

• dapoxetine
• an antidepressant
• erectile-function medicine
• medication for cardiovascular conditions.

Start Your Free Assessment

What Makes PE Evidence Reliable?

The most useful evidence usually has several features.

Look for:

Human participants diagnosed with PE

Animal research is useful for biology but cannot establish human treatment effectiveness.

Randomisation

This reduces allocation bias.

Placebo or active comparison

Without comparison, natural improvement can be mistaken for treatment effect.

Adequate participant numbers

Small studies produce less precise results.

Validated outcomes

IELT, perceived control and validated PE questionnaires are more useful than vague reports of “better performance”.

Adverse-effect reporting

Effectiveness without safety information is incomplete.

Replication

One result becomes more convincing when independent researchers reproduce it.

Does a Published Study Mean the Treatment Is Recommended?

No.

A treatment can be studied without becoming part of routine clinical care.

Researchers deliberately investigate treatments whose effectiveness is uncertain.

Clinical guidelines consider the total evidence base, not simply whether one paper exists.

For example, botulinum toxin injections were proposed as a PE treatment, but a 2025 meta-analysis of three randomised trials involving 228 participants concluded that botulinum toxin-A did not provide meaningful PE benefit.

Negative research is just as important as positive research.

Why Are Negative Studies Important?

Without negative studies, ineffective treatments can appear more promising than they really are.

A good research system asks:

Does it work?

not

How can we prove it works?

When a well-designed trial shows no meaningful advantage, that information protects patients from:

• ineffective treatments
• unnecessary cost
• adverse effects
• invasive procedures.

Are Combination Treatments Being Studied?

Yes.

Researchers are studying whether combining treatments helps men who do not respond adequately to one intervention.

A registered clinical study, for example, investigated combined dapoxetine with tadalafil or dapoxetine with lidocaine spray in men with lifelong PE who had not responded adequately to dapoxetine alone.

However, the registry's last verified status is old and no results were posted there, so it should not be used as evidence supporting unsupervised combination treatment.

Does a ClinicalTrials.gov Entry Mean You Should Try the Treatment?

No.

Clinical-trial registries are primarily research transparency tools.

They show:

• what researchers plan to investigate
• study design
• eligibility
• participant numbers
• trial status
• planned outcomes.

The entry does not tell you that the experimental treatment is clinically appropriate for personal use.

Can You Join a Premature Ejaculation Clinical Trial?

Potentially, if a recruiting study is available and you meet its eligibility criteria.

Trials may have requirements involving:

• age
• lifelong versus acquired PE
• baseline ejaculation time
• current medicines
• other medical conditions
• previous treatment.

Eligibility is determined by the research team.

People considering a clinical trial should understand:

• whether treatment is experimental
• whether placebo is possible
• what procedures are involved
• known and unknown risks
• whether expenses are covered
• how personal data will be handled.

What Questions Should You Ask About a PE Study?

Before treating a research claim as convincing, ask:

Was it conducted in humans with diagnosed PE?

Was the study randomised?

Was there a placebo group?

How many participants were included?

Was ejaculation time actually measured?

Were control and distress also measured?

How long did treatment last?

Were adverse effects reported?

Have independent studies found the same result?

These questions are particularly important for supplement claims.

Premature Ejaculation Research: Key Takeaway

Premature ejaculation has a meaningful and continually developing clinical research base, but not every treatment appearing online has the same level of evidence.

A 2025 umbrella review examined 44 meta-analyses covering 65 randomised pharmacological trials. Treatments including SSRIs and topical local anaesthetics showed measurable benefits, although overall trial quality remained variable and longer follow-up was often needed.

Research is also expanding into non-drug approaches.

In 2026, clinical-trial registries include studies examining:

pelvic-floor training

biofeedback

electromagnetic stimulation

and

new experimental medicines.

These trials are useful because they may shape future treatment. They should not, however, be confused with proven clinical options before their results are available and independently evaluated.

The evidence for maca root is much weaker for PE.

Human maca studies have examined desire, semen quality, hormone levels and erection-related outcomes, but they do not currently provide convincing PE-specific evidence showing that maca reliably increases ejaculation latency.

The evidence for garlic is weaker still.

Garlic appears in some traditional medicinal references associated with PE, but current clinical evidence does not establish ordinary garlic intake or garlic supplements as an effective treatment for delaying ejaculation.

For anyone searching “premature ejaculation study,” “premature ejaculation research,” “premature ejaculation clinical trials,” “maca premature ejaculation evidence,” “maca root premature ejaculation study” or “garlic premature ejaculation evidence,” the most useful conclusion is:

There is substantial clinical research into PE, but maca and garlic currently lack the direct, high-quality PE-specific human evidence available for established treatments. A supplement should not be described as proven simply because it has been studied for another male-health outcome or appears in traditional medicine.

Medical Disclaimer

This article provides general educational information about premature ejaculation research and should not be interpreted as recommending an experimental treatment, supplement or clinical-trial regimen. Results from laboratory research, animal experiments, individual case studies and trial registrations do not establish effectiveness in routine care. Supplements can also cause adverse effects or interact with medicines. Persistent PE should be assessed by an appropriately qualified healthcare professional before treatment is selected.